Mark Jones, PhD PMP
Mark has dedicated his career to the development of antimicrobials. Originally trained as a microbiologist at the University of Bristol Medical School, UK, Mark worked as a clinical scientist at the UK National Mycology Laboratory before moving to the University of Utrecht Medical Center, NL where he established a research group focusing on AMR projects across Europe. His career as a developer of new antimicrobials kicked off with what is today Eurofins, where he lead microbiology development programs for global pharmaceutical clients. Since 2007 Mark has been a key stakeholder at Basilea, Switzerland, where he is now Head of Development specializing in the research and development of antibacterials and antifungals, and successfully bringing ceftobiprole and isavuconazole to the global market. Mark has published more than a 100 peer reviewed papers in the field of infectious disease and AMR and is a well know voice in today’s international AMR community; a Board Member of the BEAM Alliance and Board Member of the Swiss Round Table for Antibiotics.